Flagship growth driver, GreenCross Flebogamma DIF powers global IVIG lineup

With Flebogamma DIF, Green Cross leans on a high-purity IVIG therapy as a flagship biopharma product in immunology and hospital care, supported by US and EU approvals and steady global demand for plasma-derived medicines.

Edited by ad hoc news Flagship & Bestseller Desk. Reviewed before publication on 06/15/2026 at 10:53 AM ET. Details in the imprint.

Green Cross leans heavily on its flagship intravenous immunoglobulin therapy Flebogamma DIF, a high-purity 5 percent and 10 percent IVIG preparation used to treat primary immunodeficiency and select autoimmune indications worldwide. According to the US prescribing information, the product is indicated for primary immunodeficiency (PID) and chronic primary immune thrombocytopenia (ITP) in adults, positioning it squarely in the core hospital immunology market. The official US label details these indications and dosing.

How Flebogamma DIF fits Green Cross’s flagship plasma portfolio

Flebogamma DIF is a human normal immunoglobulin (IVIG) solution manufactured from large pools of human plasma, undergoing multiple virus inactivation and removal steps, including solvent/detergent treatment, pasteurization and nanofiltration, to minimize the risk of pathogen transmission. The formulation is stabilized with D-sorbitol and glycine, and is supplied in ready-to-use vials in different sizes and concentrations for intravenous infusion in hospital or specialized infusion center settings. The dedicated product site highlights the manufacturing process and available strengths.

Clinically, Flebogamma DIF serves as replacement therapy in patients with primary immunodeficiency syndromes who cannot produce sufficient functional antibodies, reducing the frequency and severity of bacterial infections when administered regularly. In chronic primary ITP, the high-dose IVIG regimen can increase platelet counts and reduce bleeding risk in adults, often used when a rapid response is needed or other treatments have failed, according to regulatory documents and hematology guidelines. Its 10 percent formulation allows shorter infusion times compared with older 5 percent-only IVIG preparations, which can be relevant for infusion center throughput and patient convenience.

Green Cross markets Flebogamma DIF as part of a broader plasma-derivative portfolio that also includes albumin and coagulation factor concentrates, and the company has expanded manufacturing capacity in Korea and Spain to secure plasma supply and meet global demand for IVIG products. Company disclosures show that immunoglobulins represent a substantial share of its biopharmaceutical revenue mix, and Flebogamma DIF is one of the lead brands in key regions including the United States, Europe and parts of Asia. The product has obtained approvals from multiple regulators, including the US Food and Drug Administration and the European Medicines Agency, underlining its role as a mature, volume-driven therapy in Green Cross’s line-up. Green Cross’s English-language product listing describes Flebogamma DIF as a major IVIG export product.

Within the hospital and specialty-clinic channel, Flebogamma DIF competes against IVIG brands from global plasma players such as CSL Behring, Takeda and Grifols, with differentiation through concentration options, safety profile and infusion characteristics. As a solvent/detergent-treated product with additional nanofiltration, Flebogamma DIF emphasizes viral safety and low IgA content, which can be relevant for patients with IgA deficiency who are at higher risk of anaphylactic reactions to some immunoglobulin preparations. The product’s flexibility in dosing across a range of body weights and indications, backed by established dosing regimens in regulatory labeling, maintains its status as a workhorse therapy rather than a niche or ultra-rare disease product.

For Green Cross, sustained demand for IVIG in both developed and emerging markets makes Flebogamma DIF strategically important as a cash-generating, flagship therapy that supports ongoing investment in newer biologics and vaccine projects. Shares of Green Cross (ISIN KR7006280002) last traded on the Korea Exchange (KRX) at KRW 124,600 on 06/13/2026.

Flebogamma DIF quick profile: the key facts

• Product: Flebogamma DIF
• Manufacturer: Green Cross
• Category: Flagship plasma-derived IVIG therapy
• Launch date: 1999 (initial EU approval) / 2006 (US approval)
• MSRP / Price: Hospital-negotiated; typically per-gram pricing varies by market and contract
• Availability: Hospital and specialty infusion centers in the US, EU, Korea and other regulated markets
• Target audience: Patients with primary immunodeficiency or chronic primary immune thrombocytopenia requiring IVIG therapy
• Key differentiator / USP: High-purity, solvent/detergent-treated IVIG with both 5 percent and 10 percent concentrations and extensive viral safety steps

This article was a.i.-assisted and editorially reviewed. Product information without warranty; prices and availability may change at short notice. Not investment advice and not a buy or sell recommendation. Trading involves risk up to and including the total loss of invested capital.